GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (SHSE:688235) » Definitions » Accounts Payable

BeiGene (SHSE:688235) Accounts Payable : ¥2,949 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is BeiGene Accounts Payable?

BeiGene's Accounts Payable for the quarter that ended in Dec. 2024 was ¥2,949 Mil.

BeiGene's quarterly Accounts Payable declined from Jun. 2024 (¥2,416 Mil) to Sep. 2024 (¥2,176 Mil) but then increased from Sep. 2024 (¥2,176 Mil) to Dec. 2024 (¥2,949 Mil).

BeiGene's annual Accounts Payable increased from Dec. 2022 (¥2,055 Mil) to Dec. 2023 (¥2,250 Mil) and increased from Dec. 2023 (¥2,250 Mil) to Dec. 2024 (¥2,949 Mil).


BeiGene Accounts Payable Historical Data

The historical data trend for BeiGene's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Accounts Payable Chart

BeiGene Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,516.84 1,671.30 2,055.13 2,249.96 2,948.66

BeiGene Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,249.96 2,567.88 2,415.98 2,176.10 2,948.66

BeiGene Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.


BeiGene Accounts Payable Related Terms

Thank you for viewing the detailed overview of BeiGene's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


BeiGene Business Description

Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

BeiGene Headlines

No Headlines